Clinical trial
A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2/3)
NCT04098744 is registered in ClinicalTrials.gov with Frantz Viral Therapeutics, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2/3)
- Lead sponsor
- Frantz Viral Therapeutics, LLC
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 9, 2020
- Completion date
- December 31, 2026
- Enrollment
- 78 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
cervical dysplasia, cin 2/3, hpv infection, hpv related disease, pre-cancerous dysplasia